Summary
63 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 163 USD is left as net profit.
- It holds more cash than debt: $196.6M against $64.8M.
- You pay 1.2 USD for 1 USD of yearly profit, little for its sector.
What to watch
- Revenue fell by 5.8% a year over the last 3 years.
- Its last loss-making year was 2 years ago.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapP/E against the industry (Biotechnology)
Today you pay 1.2 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 6.8% a year over 5 years. Over the last 3 years it fell by 5.8% a year.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 37 USD
- Research and development 1.7 USD
- Sales and administration 104 USD
- Taxes and other -206 USD
- Net profit 163 USD
Net profit, industry median (Biotechnology) 5.0 USD
Out of every 100 USD of revenue, 163 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 10
- Hold 0
- Sell 0
No analyst has published a price target.
100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Qbrexza 66%
- Accutane 34%
By region
The company reports no revenue by region.
Qbrexza brings in 66% of revenue.
Segments in detail